TEVA
Teva Pharmaceutical·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Strong Buy"
High Gross Profit Margin
Gap Up
Significant Net Income Growth
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TEVA
Teva Pharmaceutical Industries Limited
The largest generic drug manufacturer and one of the largest pharmaceutical company in the world
Pharmaceutical
02/13/1944
05/30/2012
New York Stock Exchange
36,830
12-31
Depository Receipts (Ordinary Shares)
124 Dvora HaNevi’a St., Tel Aviv, ISRAEL, 6944020
Manufacturers of generic and innovative drugs.
Teva Pharmaceutical Industries Limited was incorporated in Israel on February 13, 1944. The company is a global pharmaceutical company dedicated to helping patients around the world obtain affordable medicines and benefit from innovations that improve health. The company's mission is to become a global leader in generic, innovative and biopharmaceutical drugs, improving the lives of patients. The company operates globally, is headquartered in Israel, and has significant operations in the United States, Europe and many other markets around the world.
Earnings Call
Q1/2025
Estimate EPS0.46
Actual EPS0.52
Estimate Revenue3.99B
Actual Revenue3.90B
Teva's Q1 2025 Earnings Call: Unpacking Contradictions in Generics Strategy, Margins, and Market Dynamics
May 19,2025 04:24
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TEVA has released its 2025 Q3 earnings. EPS was reported at 0.78, versus the expected 0.67, beating expectations. The chart below visualizes how TEVA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TEVA has released its 2025 Q3 earnings report, with revenue of 4.48B, reflecting a YoY change of 3.42%, and net profit of 434.00M, showing a YoY change of 211.28%. The Sankey diagram below clearly presents TEVA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
